Second Affiliated Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Evid Based Complement Alternat Med. 2013;2013:827915. doi: 10.1155/2013/827915. Epub 2013 Sep 23.
Objective. To describe the clinical use of n-of-1 RCTs for kidney-Yin deficiency syndrome that is a traditional Chinese medicine syndrome in publicly clinical practice in China. Methods. Our study included patients with kidney-Yin deficiency syndrome, using a within-patient, randomized, double-blind, crossover comparison of Liuwei Dihuang decoction versus placebo. Outcome Measures. Primary outcome measures included number of individual completion rates, response rate, and post-n-of-1 RCTs decisions. Secondary measures were the whole group score of individual Likert scale, SF-36 questionnaire. Results. Fifty patients were recruited and 3 were not completed. Forty-seven patients completed 3 pairs of periods, 3 (6.38%) were responders, 28 (59.57%) were nonresponders, and 16 (34.05%) were possible responders. Doctors and patients used the trial results to making decision. Three responders stayed on the medication management, 28 nonresponders ceased the LDD, 7 patients of the 16 possible responders could not give clear decision, and the others kept the same medication station. Among the whole group, neither the individual Likert score nor the SF-36 showed any statistical differences between LDD and placebo. Discussion. More attention should be paid to choose experienced TCM doctor as investigator and keep the simulant same with test medication in n-of-1 RCTs of TCM and sufficiently biological half-life period of Chinese medicine compound.
目的。描述 n-of-1 RCT 在中医肾阴虚证临床实践中的应用。方法。我们的研究纳入了肾阴虚证患者,采用患者内随机、双盲、交叉比较六味地黄汤与安慰剂。主要结局指标包括个体完成率、反应率和 n-of-1 RCT 后决策。次要指标是个体 Likert 量表、SF-36 问卷的整体评分。结果。共招募了 50 名患者,其中 3 名未完成。47 名患者完成了 3 对周期,3 名(6.38%)为反应者,28 名(59.57%)为无反应者,16 名(34.05%)为可能反应者。医生和患者根据试验结果做出决策。3 名反应者继续药物治疗,28 名无反应者停止使用 LDD,16 名可能反应者中的 7 名无法做出明确决定,其余人继续使用相同的药物。在整个组中,无论是个体 Likert 评分还是 SF-36,六味地黄汤与安慰剂之间均无统计学差异。讨论。在中医 n-of-1 RCT 中,应更加注意选择有经验的中医医生作为研究者,并保持模拟药物与试验药物相同,同时保证中药复方有足够的生物半衰期。